Acetylsalicylic acid and dihydroartemisinin combined therapy on experimental malaria-associated acute lung injury: analysis of lung function and the inflammatory process

Helena D'Anunciação de Oliveira,Camila Nunes Batista,Maiara Nascimento Lima,Ana Carolina Lima,Beatriz Amanda Barbosa Rangel dos Passos,Rodrigo Jose Rocha Xavier Freitas,Johnatas Dutra Silva,Debora Gonçalves Xisto,Marcos Vinícius Rangel-Ferreira,Marcelo Pelajo,Patricia Rieken Macedo Rocco,Flávia Lima Ribeiro-Gomes,Hugo Caire de Castro Faria-Neto,Tatiana Maron-Gutierrez
DOI: https://doi.org/10.1186/s12936-024-05017-7
2024-09-22
Malaria Journal
Abstract:Severe malaria can cause respiratory symptoms, which may lead to malaria-acute lung injury (MA-ALI) due to inflammation and damage to the blood-gas barrier. Patients with severe malaria also often present thrombocytopenia, and the use of acetylsalicylic acid (ASA), a commonly used non-steroidal anti-inflammatory drug with immunomodulatory and antiplatelet effects, may pose a risk in regions where malaria is endemic. Thus, this study aimed to investigate the systemic impact of ASA and dihydroartemisinin (DHA) on ALI induced in mice by Plasmodium berghei NK65 ( Pb NK65).
infectious diseases,tropical medicine,parasitology
What problem does this paper attempt to address?